T cell engineering is a novel therapeutic strategy designed to rapidly establish potent tumour immunity. Tumour antigen targeting and enhanced T cell functionality may be achieved through the expression of synthetic receptors for antigen, known as chimeric antigen receptors (CARs).
Second-generation CARs, which provide co-stimulatory signals in addition to initiating T cell activation, have shown impressive complete remissions in patients with B cell malignancies, especially acute lymphoblastic leukaemia and B cell lymphomas.
Co-stimulation is required for effective proliferation, persistence and function of CAR T cells.
CD28 and 4-1BB provide distinct, complementary co-stimulatory support to T cells, although their effect within CAR structures cannot be equated to that of the native receptors.
Both 28ζ and BBζ CARs show promising clinical results against B cell malignancies, with different tumour-killing kinetics. Inclusion of CD28 appears to mediate faster tumour reduction, whereas 4-1BB appears to promote T cell persistence.
The design and study of CARs is giving rise to the new field of immunopharmacology.
Second-generation chimeric antigen receptors (CARs) retarget and reprogramme T cells to augment their antitumour efficacy. The combined activating and co-stimulatory domains incorporated in these CARs critically determine the function, differentiation, metabolism and persistence of engineered T cells. CD19-targeted CARs that incorporate CD28 or 4-1BB signalling domains are the best known to date. Both have shown remarkable complete remission rates in patients with refractory B cell malignancies. Recent data indicate that CD28-based CARs direct a brisk proliferative response and boost effector functions, whereas 4-1BB-based CARs induce a more progressive T cell accumulation that may compensate for less immediate potency. These distinct kinetic features can be exploited to further develop CAR-based T cell therapies for a variety of cancers. A new field of immunopharmacology is emerging.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Molecular Cancer Open Access 19 October 2022
The journey of CAR-T therapy in hematological malignancies
Molecular Cancer Open Access 08 October 2022
CAR-T cell potency: from structural elements to vector backbone components
Biomarker Research Open Access 19 September 2022
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Sadelain, M., Riviere, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35–45 (2003).
Ho, W. Y., Blattman, J. N., Dossett, M. L., Yee, C. & Greenberg, P. D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3, 431–437 (2003).
Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
Dossett, M. L. et al. Adoptive immunotherapy of disseminated leukemia with TCR-transduced, CD8+ T cells expressing a known endogenous TCR. Mol. Ther. 17, 742–749 (2009).
Sadelain, M., Brentjens, R. & Riviere, I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215–223 (2009).
Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817–4828 (2011).
Brentjens, R. J. et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013). The first report of complete remission in four out of four subjects with ALL following CD19 CAR T cell therapy.
Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).
Davila, M. L. et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6, 224ra25 (2014).
Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a Phase 1 dose-escalation trial. Lancet 385, 517–528 (2015).
Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
Porter, D. L., Kalos, M., Zheng, Z., Levine, B. & June, C. Chimeric antigen receptor therapy for B-cell malignancies. J. Cancer 2, 331–332 (2011).
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011). The first case-report of complete remission in two out of three subjects with CCL following CD19 CAR T cell therapy.
Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).
Kochenderfer, J. N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720 (2012).
Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor. Nat. Biotechnol. 20, 70–75 (2002). The first report of sustained T cell expansion and functionality upon repeated exposure to antigen using a second-generation CAR (28ζ) transduced in human primary T cells.
Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676–684 (2004). The first report of the antitumor efficacy of a BBζ CAR in an ALL xenograft model.
Zinkernagel, R. M. & Doherty, P. C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248, 701–702 (1974).
Dembic, Z. et al. Transfer of specificity by murine α and β T-cell receptor genes. Nature 320, 232–238 (1986).
Boomer, J. S. & Green, J. M. An enigmatic tail of CD28 signaling. Cold Spring Harb. Perspect. Biol. 2, a002436 (2010).
Jenkins, M. K., Chen, C. A., Jung, G., Mueller, D. L. & Schwartz, R. H. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J. Immunol. 144, 16–22 (1990).
Weissman, A. M. et al. Molecular cloning of the ζ chain of the T cell antigen receptor. Science 239, 1018–1021 (1988).
Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891–901 (1991).
Romeo, C. & Seed, B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64, 1037–1046 (1991).
Letourneur, F. & Klausner, R. D. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor ζ family proteins. Proc. Natl Acad. Sci. USA 88, 8905–8909 (1991).
Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720–724 (1993). This paper shows redirection of T cell hybridoma specificity through the coupling of an scFv to a T cell-activating CD3ζ or Fcγ receptor domain.
Brocker, T., Peter, A., Traunecker, A. & Karjalainen, K. New simplified molecular design for functional T cell receptor. Eur. J. Immunol. 23, 1435–1439 (1993).
Brocker, T. & Karjalainen, K. Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 181, 1653–1659 (1995).
Brocker, T. Chimeric Fv-ζ or Fv-ɛ receptors are not sufficient to induce activation or cytokine production in peripheral T cells. Blood 96, 1999–2001 (2000).
Gallardo, H. F., Tan, C., Ory, D. & Sadelain, M. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90, 952–957 (1997).
Gong, M. C. et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123–127 (1999).
Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619–626 (1998).
Finney, H. M., Lawson, A. D., Bebbington, C. R. & Weir, A. N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791–2797 (1998).
Hombach, A. et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J. Immunol. 167, 6123–6131 (2001).
Shahinian, A. et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609–612 (1993).
Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 13, 227–242 (2013).
Hutloff, A. et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 397, 263–266 (1999).
Watanabe, N. et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4, 670–679 (2003).
Brunet, J. F. et al. A new member of the immunoglobulin superfamily — CTLA-4. Nature 328, 267–270 (1987).
Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).
Hansen, J. A., Martin, P. J. & Nowinski, R. C. Monoclonal-antibodies identifying a novel T-cell antigen and Ia antigens of human-lymphocytes. Immunogenetics 10, 247–260 (1980).
Aruffo, A. & Seed, B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Natl Acad. Sci. USA 84, 8573–8577 (1987).
Yamada, H. et al. Monoclonal antibody 9.3 and anti-CD11 antibodies define reciprocal subsets of lymphocytes. Eur. J. Immunol. 15, 1164–1168 (1985).
Gross, J. A., St John, T. & Allison, J. P. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J. Immunol. 144, 3201–3210 (1990).
Bour-Jordan, H. & Bluestone, J. A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol. Rev. 229, 41–66 (2009).
Woerly, G. et al. Human eosinophils express and release IL-13 following CD28-dependent activation. J. Leukoc. Biol. 72, 769–779 (2002).
Kozbor, D., Moretta, A., Messner, H. A., Moretta, L. & Croce, C. M. Tp44 molecules involved in antigen-independent T cell activation are expressed on human plasma cells. J. Immunol. 138, 4128–4132 (1987).
Venuprasad, K. et al. Immunobiology of CD28 expression on human neutrophils. I. CD28 regulates neutrophil migration by modulating CXCR-1 expression. Eur. J. Immunol. 31, 1536–1543 (2001).
Williams, J. A. et al. Regulation of thymic NKT cell development by the B7–CD28 costimulatory pathway. J. Immunol. 181, 907–917 (2008).
Viola, A. & Lanzavecchia, A. T cell activation determined by T cell receptor number and tunable thresholds. Science 273, 104–106 (1996).
Manickasingham, S. P., Anderton, S. M., Burkhart, C. & Wraith, D. C. Qualitative and quantitative effects of CD28/B7-mediated costimulation on naive T cells in vitro. J. Immunol. 161, 3827–3835 (1998).
Diehn, M. et al. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl Acad. Sci. USA 99, 11796–11801 (2002).
Riley, J. L. et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc. Natl Acad. Sci. USA 99, 11790–11795 (2002).
June, C. H., Ledbetter, J. A., Gillespie, M. M., Lindsten, T. & Thompson, C. B. T-cell proliferation involving the CD28 pathway is associated with cyclosporine-resistant interleukin 2 gene expression. Mol. Cell. Biol. 7, 4472–4481 (1987).
Smeets, R. L. et al. Molecular pathway profiling of T lymphocyte signal transduction pathways; Th1 and Th2 genomic fingerprints are defined by TCR and CD28-mediated signaling. BMC Immunol. 13, 12 (2012).
Boonen, G. J. et al. CD28 induces cell cycle progression by IL-2-independent down-regulation of p27kip1 expression in human peripheral T lymphocytes. Eur. J. Immunol. 29, 789–798 (1999).
Radvanyi, L. G. et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J. Immunol. 156, 1788–1798 (1996).
Thomas, R. M., Gao, L. & Wells, A. D. Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J. Immunol. 174, 4639–4646 (2005).
Gubser, P. M. et al. Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch. Nat. Immunol. 14, 1064–1072 (2013).
Yang, K. et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 39, 1043–1056 (2013).
Faris, M., Kokot, N., Lee, L. & Nel, A. E. Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in jurkat T cells. Evidence for the importance of Ras in a pathway that is controlled by dual receptor stimulation. J. Biol. Chem. 271, 27366–27373 (1996).
Rao, S., Gerondakis, S., Woltring, D. & Shannon, M. F. c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J. Immunol. 170, 3724–3731 (2003).
Murayama, A. et al. A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. EMBO J. 25, 1081–1092 (2006).
Grogan, J. L. et al. Early transcription and silencing of cytokine genes underlie polarization of T helper cell subsets. Immunity 14, 205–215 (2001).
Jacobs, S. R. et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180, 4476–4486 (2008).
Frauwirth, K. A. et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 16, 769–777 (2002).
Kane, L. P., Andres, P. G., Howland, K. C., Abbas, A. K. & Weiss, A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines. Nat. Immunol. 2, 37–44 (2001).
Rathmell, J. C., Farkash, E. A., Gao, W. & Thompson, C. B. IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 167, 6869–6876 (2001).
Vander Heiden, M. G. et al. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol. Cell. Biol. 21, 5899–5912 (2001).
Rathmell, J. C., Vander Heiden, M. G., Harris, M. H., Frauwirth, K. A. & Thompson, C. B. In the absence of extrinsic signals, nutrient utilization by lymphocytes is insufficient to maintain either cell size or viability. Mol. Cell 6, 683–692 (2000).
Acuto, O. & Michel, F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3, 939–951 (2003).
Boise, L. H. et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3, 87–98 (1995).
Wan, Y. Y. & DeGregori, J. The survival of antigen-stimulated T cells requires NFκB-mediated inhibition of p73 expression. Immunity 18, 331–342 (2003).
Kirchhoff, S., Muller, W. W., Li-Weber, M. & Krammer, P. H. Up-regulation of c-FLIPshort and reduction of activation-induced cell death in CD28-costimulated human T cells. Eur. J. Immunol. 30, 2765–2774 (2000).
Gimmi, C. D., Freeman, G. J., Gribben, J. G., Gray, G. & Nadler, L. M. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Natl Acad. Sci. USA 90, 6586–6590 (1993).
Beier, K. C. et al. Induction, binding specificity and function of human ICOS. Eur. J. Immunol. 30, 3707–3717 (2000).
Johnson-Leger, C., Christensen, J. & Klaus, G. G. CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells. Int. Immunol. 10, 1083–1091 (1998).
Kim, J. O., Kim, H. W., Baek, K. M. & Kang, C. Y. NF-κB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells. FEBS Lett. 541, 163–170 (2003).
Borowski, A. B. et al. Memory CD8+ T cells require CD28 costimulation. J. Immunol. 179, 6494–6503 (2007).
Fuse, S., Zhang, W. & Usherwood, E. J. Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J. Immunol. 180, 1148–1157 (2008).
Hathcock, K. S., Laszlo, G., Pucillo, C., Linsley, P. & Hodes, R. J. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180, 631–640 (1994).
Fleischer, J. et al. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology 89, 592–598 (1996).
Eck, S. C., Chang, D., Wells, A. D. & Turka, L. A. Differential down-regulation of CD28 by B7-1 and B7-2 engagement. Transplantation 64, 1497–1499 (1997).
Lewis, D. E., Merched-Sauvage, M., Goronzy, J. J., Weyand, C. M. & Vallejo, A. N. Tumor necrosis factor-α and CD80 modulate CD28 expression through a similar mechanism of T-cell receptor-independent inhibition of transcription. J. Biol. Chem. 279, 29130–29138 (2004).
Berg, M. & Zavazava, N. Regulation of CD28 expression on CD8+ T cells by CTLA-4. J. Leukoc. Biol. 83, 853–863 (2008).
Habib-Agahi, M., Jaberipour, M. & Searle, P. F. 4-1BBL costimulation retrieves CD28 expression in activated T cells. Cell. Immunol. 256, 39–46 (2009).
Topp, M. S. et al. Restoration of CD28 expression in CD28− CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J. Exp. Med. 198, 947–955 (2003).
Peach, R. J. et al. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. J. Exp. Med. 180, 2049–2058 (1994).
Linsley, P. S. et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1, 793–801 (1994).
Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600–603 (2011).
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H. & Riley, J. L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173, 945–954 (2004).
Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2006).
Riley, J. L. PD-1 signaling in primary T cells. Immunol. Rev. 229, 114–125 (2009).
Croft, M. Costimulation of T cells by OX40, 4-1BB, and CD27. Cytokine Growth Factor Rev. 14, 265–273 (2003).
Kwon, B. S. et al. Isolation and initial characterization of multiple species of T-lymphocyte subset cDNA clones. Proc. Natl Acad. Sci. USA 84, 2896–2900 (1987).
Kwon, B. S. & Weissman, S. M. cDNA sequences of two inducible T-cell genes. Proc. Natl Acad. Sci. USA 86, 1963–1967 (1989).
Schwarz, H., Tuckwell, J. & Lotz, M. A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene 134, 295–298 (1993).
Schwarz, H., Valbracht, J., Tuckwell, J., von Kempis, J. & Lotz, M. ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 85, 1043–1052 (1995).
Lee, S. J. et al. 4-1BB signal stimulates the activation, expansion, and effector functions of γδ T cells in mice and humans. Eur. J. Immunol. 43, 1839–1848 (2013).
Melero, I., Johnston, J. V., Shufford, W. W., Mittler, R. S. & Chen, L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell. Immunol. 190, 167–172 (1998).
Zhang, X. et al. CD137 promotes proliferation and survival of human B cells. J. Immunol. 184, 787–795 (2010).
Wilcox, R. A. et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J. Immunol. 168, 4262–4267 (2002).
Drenkard, D. et al. CD137 is expressed on blood vessel walls at sites of inflammation and enhances monocyte migratory activity. FASEB J. 21, 456–463 (2007).
von Kempis, J., Schwarz, H. & Lotz, M. Differentiation-dependent and stimulus-specific expression of ILA, the human 4-1BB-homologue, in cells of mesenchymal origin. Osteoarthritis Cartilage 5, 394–406 (1997).
Futagawa, T. et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int. Immunol. 14, 275–286 (2002).
Goodwin, R. G. et al. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 23, 2631–2641 (1993).
Pollok, K. E. et al. 4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-μ-primed splenic B cells. Eur. J. Immunol. 24, 367–374 (1994).
Alderson, M. R. et al. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24, 2219–2227 (1994).
Polte, T., Jagemann, A., Foell, J., Mittler, R. S. & Hansen, G. CD137 ligand prevents the development of T-helper type 2 cell-mediated allergic asthma by interferon-γ-producing CD8+ T cells. Clin. Exp. Allergy 37, 1374–1385 (2007).
Won, E. Y. et al. The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily. J. Biol. Chem. 285, 9202–9210 (2010).
Vinay, D. S., Cha, K. & Kwon, B. S. Dual immunoregulatory pathways of 4-1BB signaling. J. Mol. Med. (Berl.) 84, 726–736 (2006).
Dawicki, W. & Watts, T. H. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur. J. Immunol. 34, 743–751 (2004).
Takahashi, C., Mittler, R. S. & Vella, A. T. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J. Immunol. 162, 5037–5040 (1999).
Lee, S. W. et al. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J. Immunol. 177, 4464–4472 (2006).
Pulle, G., Vidric, M. & Watts, T. H. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J. Immunol. 176, 2739–2748 (2006).
Nam, K. O. et al. Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. J. Immunol. 174, 1898–1905 (2005).
Daniel-Meshulam, I., Horovitz-Fried, M. & Cohen, C. J. Enhanced antitumor activity mediated by human 4-1BB-engineered T cells. Int. J. Cancer 133, 2903–2913 (2013).
Cannons, J. L. et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J. Immunol. 167, 1313–1324 (2001).
Wen, T., Bukczynski, J. & Watts, T. H. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J. Immunol. 168, 4897–4906 (2002).
Jang, I. K., Lee, Z. H., Kim, Y. J., Kim, S. H. & Kwon, B. S. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-κB. Biochem. Biophys. Res. Commun. 242, 613–620 (1998).
Arch, R. H. & Thompson, C. B. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Mol. Cell. Biol. 18, 558–565 (1998).
Saoulli, K. et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187, 1849–1862 (1998).
Zheng, C., Kabaleeswaran, V., Wang, Y., Cheng, G. & Wu, H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol. Cell 38, 101–113 (2010).
Sabbagh, L., Pulle, G., Liu, Y., Tsitsikov, E. N. & Watts, T. H. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J. Immunol. 180, 8093–8101 (2008).
McPherson, A. J., Snell, L. M., Mak, T. W. & Watts, T. H. Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells. J. Biol. Chem. 287, 23010–23019 (2012).
Cannons, J. L., Choi, Y. & Watts, T. H. Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J. Immunol. 165, 6193–6204 (2000).
Hauer, J. et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs. Proc. Natl Acad. Sci. USA 102, 2874–2879 (2005).
Lee, H. W., Nam, K. O., Park, S. J. & Kwon, B. S. 4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur. J. Immunol. 33, 2133–2141 (2003).
DeBenedette, M. A., Shahinian, A., Mak, T. W. & Watts, T. H. Costimulation of CD28− T lymphocytes by 4-1BB ligand. J. Immunol. 158, 551–559 (1997).
Chu, N. R., DeBenedette, M. A., Stiernholm, B. J., Barber, B. H. & Watts, T. H. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28− T cells. J. Immunol. 158, 3081–3089 (1997).
Bukczynski, J., Wen, T. & Watts, T. H. Costimulation of human CD28− T cells by 4-1BB ligand. Eur. J. Immunol. 33, 446–454 (2003).
Fann, M. et al. Gene expression characteristics of CD28null memory phenotype CD8+ T cells and its implication in T-cell aging. Immunol. Rev. 205, 190–206 (2005).
Ahmad, H. T., Mansooreh, J., Fereshteh, M. & Mojtaba, H. Changes in lymphocytes' telomerase activity by 4-1BB costimulation. J. Cancer Res. Ther. 10, 998–1003 (2014).
Hendriks, J. et al. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J. Immunol. 175, 1665–1676 (2005).
Shuford, W. W. et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186, 47–55 (1997).
Sabbagh, L., Snell, L. M. & Watts, T. H. TNF family ligands define niches for T cell memory. Trends Immunol. 28, 333–339 (2007).
DeBenedette, M. A. et al. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J. Immunol. 163, 4833–4841 (1999).
Kwon, B. S. et al. Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. 168, 5483–5490 (2002).
Watts, T. H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23–68 (2005).
Humphreys, I. R. et al. Biphasic role of 4-1BB in the regulation of mouse cytomegalovirus-specific CD8+ T cells. Eur. J. Immunol. 40, 2762–2768 (2010).
Wang, C. et al. Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J. Exp. Med. 209, 77–91 (2012).
Habib-Agahi, M., Phan, T. T. & Searle, P. F. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int. Immunol. 19, 1383–1394 (2007).
Zhang, B., Zhang, Y., Niu, L., Vella, A. T. & Mittler, R. S. Dendritic cells and Stat3 are essential for CD137-induced CD8 T cell activation-induced cell death. J. Immunol. 184, 4770–4778 (2010).
Frecha, C. et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 112, 4843–4852 (2008).
Unutmaz, D., KewalRamani, V. N., Marmon, S. & Littman, D. R. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes. J. Exp. Med. 189, 1735–1746 (1999).
Brentjens, R. J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426–5435 (2007).
Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl Acad. Sci. USA 106, 3360–3365 (2009).
Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453–1464 (2009).
Tammana, S. et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 21, 75–86 (2010).
Zhong, X. S., Matsushita, M., Plotkin, J., Riviere, I. & Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413–420 (2010).
Song, D. G. et al. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119, 696–706 (2012).
Santoro, S. P. et al. T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol. Res. 3, 68–84 (2014).
Finney, H. M., Akbar, A. N. & Lawson, A. D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. J. Immunol. 172, 104–113 (2004).
Guedan, S. et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124, 1070–1080 (2014).
Hombach, A. A. & Abken, H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28–OX40 signalling. Int. J. Cancer 129, 2935–2944 (2011).
Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).
Loskog, A. et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20, 1819–1828 (2006).
Kofler, D. M. et al. CD28 costimulation impairs the efficacy of a redirected T-cell antitumor attack in the presence of regulatory T cells which can be overcome by preventing Lck activation. Mol. Ther. 19, 760–767 (2011).
Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133–4141 (2012).
Sun, J. et al. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol. Ther. 18, 2006–2017 (2010).
Frigault, M. J. et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol. Res. 3, 356–367 (2015).
Gargett, T., Fraser, C. K., Dotti, G., Yvon, E. S. & Brown, M. P. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro. J. Immunother. 38, 12–23 (2015).
Song, D. G. et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71, 4617–4627 (2011).
Chattopadhyay, K. et al. Sequence, structure, function, immunity: structural genomics of costimulation. Immunol. Rev. 229, 356–386 (2009).
Long, A. H., et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581–590 (2015).
Cheadle, E. J. et al. Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J. Immunol. 92, 3654–3665 (2014).
Brentjens, R. J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279–286 (2003). The first report demonstrating the therapeutic efficacy of human CD19 CAR T cells in mice with systemic B cell malignancies.
Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE 8, e61338 (2013).
Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).
Zhang, B., Karrison, T., Rowley, D. A. & Schreiber, H. IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 118, 1398–1404 (2008).
Braumuller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 494, 361–365 (2013).
Matsushita, H. et al. Cytotoxic T lymphocytes block tumor growth both by lytic activity and γ-dependent cell-cycle arrest. Cancer Immunol. Res. 3, 26–36 (2015).
Kowolik, C. M. et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 66, 10995–11004 (2006).
Plunkett, F. J. et al. The loss of telomerase activity in highly differentiated CD8+CD28−CD27− T cells is associated with decreased Akt (Ser473) phosphorylation. J. Immunol. 178, 7710–7719 (2007).
John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636–5646 (2013).
Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24, 1160–1170 (2010).
Gros, A. et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014).
Liadi, I. et al. Individual motile CD4+ T cells can participate in efficient multikilling through conjugation to multiple tumor cells. Cancer Immunol. Res. 3, 473–482 (2015).
Crompton, J. G., Sukumar, M. & Restifo, N. P. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol. Rev. 257, 264–276 (2014).
Riddell, S. R. et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. Cancer J. 20, 141–144 (2014).
Li, Y. S., Hayakawa, K. & Hardy, R. R. The regulated expression of B lineage associated genes during B cell differentiation in bone marrow and fetal liver. J. Exp. Med. 178, 951–960 (1993).
Li, Y. S., Wasserman, R., Hayakawa, K. & Hardy, R. R. Identification of the earliest B lineage stage in mouse bone marrow. Immunity 5, 527–535 (1996).
Cooper, L. J. et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101, 1637–1644 (2003).
Kohn, D. B. et al. CARs on track in the clinic. Mol. Ther. 19, 432–438 (2011).
Jensen, M. C. et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant 16, 1245–1256 (2010).
Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102 (2010). The first case-report of a remission following CD19 CAR T cell therapy in a subject with a B cell lymphoma.
Savoldo, B. et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822–1826 (2011).
Cruz, C. R. et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122, 2965–2973 (2013).
Kochenderfer, J. N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129–4139 (2013).
Hollyman, D. et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J. Immunother. 32, 169–180 (2009).
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014).
Davila, M. L., Brentjens, R., Wang, X., Riviere, I. & Sadelain, M. How do CARs work? Early insights from recent clinical studies targeting CD19. Oncoimmunology 1, 1577–1583 (2012).
Paulos, C. M. et al. The inducible costimulator (ICOS) is critical for the development of human TH17 cells. Sci. Transl. Med. 2, 55ra78 (2010).
Oestreich, K. J. et al. Bcl-6 directly represses the gene program of the glycolysis pathway. Nat. Immunol. 15, 957–964 (2014).
Dong, C. et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409, 97–101 (2001).
Tafuri, A. et al. ICOS is essential for effective T-helper-cell responses. Nature 409, 105–109 (2001).
Burmeister, Y. et al. ICOS controls the pool size of effector-memory and regulatory T cells. J. Immunol. 180, 774–782 (2008).
Shen, C. J. et al. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma. J. Hematol. Oncol. 6, 33 (2013).
Kopf, M. et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL responses after virus infection. Immunity 11, 699–708 (1999).
Salek-Ardakani, S., Moutaftsi, M., Crotty, S., Sette, A. & Croft, M. OX40 drives protective vaccinia virus-specific CD8 T cells. J. Immunol. 181, 7969–7976 (2008).
Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271–285 (2009).
Hildebrand, J. M. et al. Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions. Immunol. Rev. 244, 55–74 (2011).
Pule, M. A. et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 12, 933–941 (2005).
Wilkie, S. et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180, 4901–4909 (2008).
Carr, J. M. et al. CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiation. Proc. Natl Acad. Sci. USA 103, 19454–19459 (2006).
Fox, C. J., Hammerman, P. S. & Thompson, C. B. The Pim kinases control rapamycin-resistant T cell survival and activation. J. Exp. Med. 201, 259–266 (2005).
Nolte, M. A., van Olffen, R. W., van Gisbergen, K. P. & van Lier, R. A. Timing and tuning of CD27–CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol. Rev. 229, 216–231 (2009).
Sentman, C. L. & Meehan, K. R. NKG2D CARs as cell therapy for cancer. Cancer J. 20, 156–159 (2014).
Chang, Y. H. et al. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 73, 1777–1786 (2013).
Lehner, M. et al. Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS ONE 7, e31210 (2012).
Song, D. G. et al. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum. Gene Ther. 24, 295–305 (2013).
Barber, A. & Sentman, C. L. Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J. Immunol. 183, 2365–2372 (2009).
Zhang, T. & Sentman, C. L. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J. Immunol. 190, 2455–2463 (2013).
Zhao, Y. et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563–5574 (2009).
Wang, J. et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum. Gene Ther. 18, 712–725 (2007).
Till, B. G. et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119, 3940–3950 (2012).
Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71–75 (2013).
Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32, 1059–1070 (2012).
Lanitis, E. et al. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 1, 43–53 (2013).
Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells Clin. Cancer Res. 19, 3153–3164 (2013).
Hudecek, M. et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125–135 (2015).
James, S. E. et al. Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. J. Immunol. 180, 7028–7038 (2008).
Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 28, 203–211 (2005).
Almasbak, H. et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther. 22, 391–403 (2015).
Fitzer-Attas, C. J., Schindler, D. G., Waks, T. & Eshhar, Z. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J. Immunol. 160, 145–154 (1998).
Bridgeman, J. S. et al. The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J. Immunol. 184, 6938–6949 (2010).
Miller, J. F. & Sadelain, M. The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 27, 439–449 (2015).
Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018–1028 (2006).
Melero, I., Hirschhorn-Cymerman, D., Morales-Kastresana, A., Sanmamed, M. F. & Wolchok, J. D. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin. Cancer Res. 19, 1044–1053 (2013).
Yao, S., Zhu, Y. & Chen, L. Advances in targeting cell surface signalling molecules for immune modulation. Nat. Rev. Drug Discov. 12, 130–146 (2013).
Gangadhar, T. C. & Vonderheide, R. H. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 11, 91–99 (2014).
Curti, B. D. et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73, 7189–7198 (2013).
de Vos, S. et al. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J. Hematol. Oncol. 7, 44 (2014).
Hussein, M. et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95, 845–848 (2010).
Furman, R. R., Forero-Torres, A., Shustov, A. & Drachman, J. G. A Phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51, 228–235 (2010).
Advani, R. et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 4371–4377 (2009).
Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020–1030 (2014).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
Hodi, F. S. et al. Ipilimumab plus sargramostim versus ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312, 1744–1753 (2014).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
M.S. is scientific co-founder of Juno Therapeutics. All other authors declare no conflict of interest.
- T cell engineering
T cell isolation and modification intended to harness antigen specificity, proliferation, persistence and/or function.
- Chimeric antigen receptor
(CAR). Fusion receptor combining antigen-recognition and T cell-activating properties. CARs consist of an antigen binding moiety (a single-chain variable fragment (scFv) or ligand), a hinge, a transmembrane domain and a cytoplasmic signalling domain, which includes a co-stimulatory domain in second-generation CARs.
- First-generation CARs
Chimeric antigen receptors (CARs) with an endodomain consisting of the cytoplasmic signalling domain of CD3ζ or the Fcγ receptor.
- Second generation CARs
Chimeric antigen receptors (CARs) that include a single co-stimulatory element within the endoplasmic domain in cis with the activating CD3ζ domain.
Rapidly acquired state of T cell unresponsiveness occurring after suboptimal activation via the T cell receptor in the absence of co-stimulation or in the presence of co-inhibitory molecules.
- Activation-induced cell death
(AICD). Apoptosis occurring following T cell activation.
Progressive hyporesponsiveness developed by T cells after repeated exposure to antigen.
- Single-chain variable fragment
(scFv). Fusion protein consisting of the variable fragments of the immunoglobulin heavy and light chains, connected by a glycine or serine linker.
- Chimeric co-stimulatory receptor
Fusion molecule coupling antigen specificity to T cell co-stimulatory signalling, without activating domains.
Also referred to as spacer domain; an extracellular component connecting the binding moiety to the transmembrane element.
- Molecular remission
Complete remission and absence of disease based on PCR analysis.
- Complete remission
Absence of disease based on imaging or biopsy analysis.
- Severe cytokine release syndrome
A clinical syndrome comprising fever, hypotension, hypoxia and/or neurological symptoms, associated with cytokine release occurring following in vivo T cell activation.
- Third-generation CARs
Chimeric antigen receptors (CARs) containing two co-stimulatory elements within the cytoplasmic domain in cis with the activating CD3ζ domain.
Rights and permissions
About this article
Cite this article
van der Stegen, S., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 14, 499–509 (2015). https://doi.org/10.1038/nrd4597
This article is cited by
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
Journal of Hematology & Oncology (2022)
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Journal of Experimental & Clinical Cancer Research (2022)
Tumor buster - where will the CAR-T cell therapy ‘missile’ go?
Molecular Cancer (2022)
CAR-T cell potency: from structural elements to vector backbone components
Biomarker Research (2022)
The journey of CAR-T therapy in hematological malignancies
Molecular Cancer (2022)